Clinical usefulness of newly developed prognostic predictive score for atezolizumab plus bevacizumab for hepatocellular carcinoma
Hideko Ohama,
Atsushi Hiraoka,
Toshifumi Tada
et al.
Abstract:Background/Aim: The present study aimed to develop detailed parameters
for prediction of prognosis for patients with unresectable
hepatocellular carcinoma (uHCC) receiving Atezolizumab plus Bevacizumab
(Atez/Bev). Methods: Between September 2020 and January 2023, the
patients treated with Atez/Bev were enrolled (n=719, males 577, median
age 74 years). Factors involved in overall survival (OS) were extracted
and a prognostic scoring system based on hazard ratio (HR) was created.
OS and progression-free survival… Show more
Set email alert for when this publication receives citations?
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.